Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

The purpose of this study is to determine the effect of the duration of androgen deprivation therapy (hormone therapy) in patients with high risk prostate cancer (2 or 3 of the following:  PSA ≥ 10.1 – 30  ng/mL, Gleason score ≥ 7, clinical stage ≥ T2c 2002 AJCC or any one of the following: PSA > 20 ng/mL, Gleason score ≥ 8, clinical stage ≥ T2c).  Some retrospective studies have suggested that androgen deprivation therapy improves biochemical outcome in men with high risk features.  What is unknown is whether no hormones or a short course (9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).

Prior to implantation, you will be randomized to either no hormones or to a 9-month course of hormonal therapy.  All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant.

For further information please contact: research@seattleprostate.com